{"entity":{"id":"paper-royer-plasma-cell-leukaemia-ifm-jco-2016","kind":"paper","name":"IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia","aka":[],"tldr":"The first prospective trial dedicated to plasma cell leukaemia showed that a bortezomib-based four-drug induction followed by stem cell transplantation could produce remissions in most patients, though relapse remained the rule.","summary":"Phase 2 study of 40 patients with primary plasma cell leukaemia treated with bortezomib, doxorubicin, cyclophosphamide and dexamethasone induction followed by autologous transplant and, for those with a donor, reduced-intensity allogeneic transplant, or a second autologous transplant and maintenance.\n\nResponse after induction was 69 percent, median progression-free survival 15.1 months and median overall survival 36.3 months, a clear improvement on historical series with median survival under a year.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2016","url":"https://doi.org/10.1200/JCO.2015.63.1929"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/27114594/"}],"tags":[],"related":[],"cancers":["plasma-cell-leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["bortezomib","cyclophosphamide","dexamethasone","doxorubicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2016,"doi":"10.1200/JCO.2015.63.1929","pmid":"27114594","authors":"Royer B, Minvielle S, Diouf M, et al.","paperType":"observational","findings":["Overall response 69 percent after induction.","Median progression-free survival 15.1 months; median overall survival 36.3 months."],"whatItMeans":"Bortezomib-based induction with early transplant consolidation became the accepted approach for fit patients with this rare aggressive disease; daratumumab-containing quadruplets are now added by extrapolation.","caveats":["Small single-arm study.","Allogeneic transplant did not clearly improve outcomes compared with tandem autologous transplant."],"changedPractice":true,"participants":40},"route":"/key-papers/paper-royer-plasma-cell-leukaemia-ifm-jco-2016/","neighbours":{"cancer":[{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/"}],"drug":[{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}